Related by context. All words. (Click for frequent words.) 70 ovarian breast 69 prostate pancreatic 67 colorectal pancreatic 65 endometrial cancers 65 ovarian lung 65 pancreatic prostate 64 breast colon 64 ovarian cancers 64 prostate breast 63 colon breast 63 lung colon 63 cervical breast 63 colorectal cancers 62 pancreatic lung 62 colorectal lung 62 breast endometrial 62 breast pancreatic 62 lung pancreatic 61 prostate cancers 61 uterine cancers 61 uterine ovarian 61 prostate colon 61 cancers 60 colon prostate 60 prostate lung 60 Li Fraumeni 60 ovarian colon 60 bladder ovarian 60 prostate colorectal 60 metastatic colorectal 60 epithelial cancers 60 pancreatic colon 60 pancreatic ovarian 60 skeletal metastases 60 breast colorectal 60 pancreatic cancers 59 breast uterine 59 gastric pancreatic 59 hormone refractory prostate 59 GISTs 59 cisplatin resistant 59 bladder cancers 59 colorectal breast 59 CYT# potent vascular disrupting 59 colorectal prostate 59 ovarian pancreatic 59 testicular cancers 59 leukaemias 59 ovarian uterine 59 lung colorectal 58 lung prostate 58 anal cancers 58 gastrointestinal cancers 58 colon pancreas 58 malignancies 58 colon cancers 58 K ras mutations 58 atypical hyperplasia 58 breast ovary 58 colon tumors 58 breast cervical 58 cetuximab Erbitux 58 colorectal ovarian 58 colon lung 58 lobular carcinoma 58 leukemia myeloma 58 squamous cell skin 58 prostate ovarian 58 testicular germ cell 57 alvespimycin 57 pancreatic bladder 57 lung ovarian 57 BRCA2 mutations 57 hormone receptor negative 57 pancreatic gastric 57 colorectal 57 IMC #B 57 nonmelanoma skin cancers 57 precursor lesions 57 intestinal polyps 57 neuroendocrine cancers 57 solid tumors 57 myelofibrosis polycythemia vera 57 gene BRCA2 57 gastric cancers 57 HER2 positive breast 56 breast prostate 56 FGFR2 56 squamous cell 56 imatinib Gleevec 56 HNSCC 56 Zolinza 56 colorectal cancer CRC 56 HER2 positive cancers 56 metastatic prostate 56 HER2 receptor 56 xenograft models 56 lung adenocarcinoma 56 endometriosis ovarian cysts 56 ovarian carcinoma 56 EGFR mutation 56 faulty BRCA genes 56 colorectal cancer 56 HGS ETR1 56 ovarian endometrial 56 LHRH receptor positive 56 carcinomas 56 carcinoma HCC 56 Squamous cell 56 melanoma basal cell 56 gefitinib Iressa 56 HER-2/neu 56 pancreatic adenocarcinoma 56 invasive carcinoma 56 Smac mimetic 56 BRAF mutation 56 lobular breast cancer 56 epithelial tumors 56 BRCA2 mutation 56 castration resistant 56 tumor subtypes 56 renal cell carcinomas 55 tumor xenograft models 55 KRAS oncogene 55 vaginal cancers 55 hematological malignancies 55 Vidaza ® 55 FLT3 55 HER2 positive metastatic breast 55 invasive ductal 55 lymphomas 55 PKCi 55 BRCA deficient 55 mutated BRCA1 55 BRCA1 mutations 55 ovarian cervical 55 T#I mutant 55 pertuzumab 55 recurrent NSCLC 55 basal cell nevus syndrome 55 osteosarcomas 55 nonsmall cell lung cancer 55 MEK inhibitors 55 bladder prostate 55 p# mutations 55 ovarian colorectal 55 pancreatic colorectal 55 EGFR HER2 55 ovarian cancer 55 Alessandro Riva 55 commonly mutated genes 55 ErbB2 positive 55 TTR gene 55 seliciclib 55 penile cancers 55 endometrial ovarian 55 serous ovarian cancer 55 anaplastic lymphoma kinase ALK 55 TGFBR1 * 6A 55 breast cancers 55 hormonally sensitive 54 monoclonal antibody therapies 54 Squamous 54 metastatic colon cancer 54 endometrial hyperplasia 54 breast tumors 54 invasive lobular 54 familial pancreatic cancer 54 Basal cell 54 Colon polyps 54 BRCA2 gene mutation 54 Vicinium TM 54 HER2 overexpression 54 breast carcinomas 54 PARP inhibitor 54 HGS ETR2 54 faulty BRCA2 gene 54 anal lesions 54 hereditary breast 54 SPINK1 54 lymphomas leukemias 54 colorectal tumors 54 castrate resistant prostate cancer 54 huC# DM4 54 hormone therapy estrogen 54 mouse xenograft models 54 gastrointestinal stromal tumors GISTs 54 BRCA mutations 54 dysplastic lesions caused 54 HER2 positive breast cancer 54 ductal carcinomas 54 hematologic malignancies 54 colon esophageal 54 CYC# 54 HuLuc# 54 hereditary breast cancer 54 HPVs 54 cervical intraepithelial neoplasia 54 situ LCIS 54 hormone gastrin 54 Carcinoid tumors 54 BRAF gene 54 penile anal 54 HER2 positive tumors 54 BRCA2 gene 54 adenocarcinomas 54 mutated BRAF gene 54 fallopian tube cancers 54 cell lung cancer 54 Zyclara Cream 54 lymphoid tumors 54 eIF 4E 54 BRCA mutation 54 hepatocellular cancer 54 ovarian tumors 54 ductal breast cancer 54 Acute myeloid leukemia AML 54 BCR ABL 54 colorectal gastric 54 Insegia 54 Basal Cell 54 Darapladib 54 evaluating tivozanib 53 neuroendocrine tumors 53 basal cell cancer 53 lobular cancer 53 OMP #M# 53 metastatic HER2 positive 53 tumors GIST 53 resistant hormone refractory 53 oligodendrogliomas 53 androgen independent 53 leukemias lymphomas 53 lenalidomide Revlimid R 53 M2 subunit 53 EGFR inhibitors 53 advanced adenomas 53 pAkt 53 estrogen receptor negative 53 squamous cell carcinomas 53 hematologic disorders 53 sarcosine 53 unresectable tumors 53 BRCA2 carriers 53 B7 H3 53 BRCA2 gene mutations 53 HPV# 53 standard chemotherapy regimens 53 mapatumumab 53 BRCA1 mutation carriers 53 trastuzumab Herceptin 53 selective kinase inhibitor 53 sarcoma melanoma 53 Aurora kinase 53 hormonal therapies 53 investigational monoclonal antibody 53 precancerous cervical 53 enzastaurin 53 IMC A# 53 basal cell carcinoma BCC 53 Proxinium TM 53 MOZOBIL 53 CanAg 53 recurrent metastatic 53 kidney urologic 53 adjuvant radiation 53 lung cancers 53 castrate resistant 53 Herceptin trastuzumab 53 luteinizing hormone releasing 53 prostate specific 53 lung carcinomas 53 endometrial cancer 53 deCODE BreastCancer 53 NSCLC 53 CBLC# 53 LRP5 53 gemcitabine chemotherapy 53 erlotinib Tarceva ® 53 squamous cell cancers 53 non metastatic osteosarcoma 53 alpha folate receptor 53 vulvar cancers 53 basal cell 53 bone metastasis 53 Epidermal Growth Factor Receptor 53 Menopausal hormone therapy 53 benign neoplasms 53 metastatic carcinoma 53 tumors 53 RGB # 53 pelvic malignancies 53 ductal cancer 53 OXi# 53 imatinib Gleevec ® 53 histologies 53 squamous non 53 gemcitabine Gemzar 53 mutated KRAS gene 53 Adjuvant chemotherapy 53 HER2 amplified 53 gynecological cancers 53 preclinical xenograft models 53 cervical dysplasia 53 JAK inhibitors 53 metastatic gastric 53 hematological cancers 53 nasopharyngeal cancer 53 lung adenocarcinomas 52 IgG1 monoclonal antibody 52 nonmetastatic 52 Imprime PGG 52 angiogenesis inhibitors 52 overexpress HER2 52 microtubule targeting 52 basal cell skin 52 neuroblastoma tumors 52 HPV vaccine protects 52 Hepatocellular Carcinoma HCC 52 hormone deprivation 52 Vandetanib 52 bowel cancers 52 recurrent ovarian cancer 52 OncoVEX GM CSF 52 EGFR pathway 52 myelomas 52 Elotuzumab 52 rectal cancers 52 inherited mutations 52 tumor metastases 52 pre cancerous polyps 52 Li Fraumeni Syndrome 52 Ceflatonin 52 cervical lesions 52 Hedgehog pathway 52 trastuzumab Herceptin ® 52 Kit CD# positive 52 hormone refractory metastatic prostate 52 prostate bladder 52 Leukemias 52 cervical carcinoma 52 progesterone receptor negative 52 axitinib 52 AEG# 52 TTR amyloidosis 52 abnormal pap smears 52 chemopreventive agent 52 endometrial tumors 52 leukemias 52 demonstrated antitumor activity 52 human papillomaviruses HPV 52 myeloproliferative neoplasms 52 VEGF inhibitors 52 microtubule inhibitor 52 HER2 ErbB2 52 hormone receptor positive 52 pleural mesothelioma 52 Uterine cancer 52 cyclin E 52 PNP inhibitor 52 prostate cancer CRPC 52 sorafenib tablets 52 vaginal lesions 52 hematologic cancers 52 biliary cancer 52 sorafenib Nexavar 52 molecular abnormalities 52 precancerous tumors 52 human papillomavirus HPV 52 HER2 positive 52 EGFR protein 52 metaglidasen 52 liver metastases 52 lymphoma subtypes 52 lung cancer NSCLC 52 Phase #/#a trial 52 AML MDS 52 KRAS mutations 52 squamous cell cancer 52 HAAH 52 Human papillomavirus HPV 52 oncogenic HPV types 52 MALT lymphoma 52 papillary renal cell carcinoma 52 leukemia AML 52 investigational immunotherapy 52 cervical cancer genital warts 52 Gardasil protects 52 genes BRCA1 52 gastrointestinal stromal tumors 52 TNF blocker therapy 52 Gleevec resistant 52 precancerous colon polyps 52 pediatric malignancies 52 colorectal carcinoma 52 esophageal tumors 52 colorectum 52 metastatic castration resistant 52 relapsed ovarian cancer 52 metastatic lesions 52 deCODE ProstateCancer TM 52 Evoltra ® 52 metastatic GIST 52 mesotheliomas 52 BRCA2 52 LHRH antagonists 52 cancer mCRC 52 gynecologic malignancy 52 squamous 52 esophageal cancers 52 neratinib 52 malignant pleural mesothelioma 52 neovascular diseases 52 ovarian 52 precancerous cervical lesions 52 endometrial carcinoma 52 CIN2 + 52 anal penile 52 breast cancer subtypes 52 olaparib 52 EpCAM 52 endostatin 52 human tumor xenografts 52 grade cervical intraepithelial 52 MyVax R 52 PSMA ADC 52 recurrent ovarian 52 endometrial 52 intravenous bisphosphonates 52 endometrial kidney 52 Human Papilloma Virus HPV 52 protein kinase inhibitor 52 ATC ovarian cancer 52 ThermoDox R 52 taxanes 52 refractory chronic lymphocytic 52 c MET 52 neoplasia PIN 51 cervical ovarian 51 inhibiting tumor 51 metachronous 51 medically inoperable 51 germline mutations 51 hepatocellular carcinoma HCC 51 tumor histology 51 lobular carcinomas 51 metastatic castrate resistant 51 seminoma 51 EGFR mutations 51 myeloproliferative disorders 51 TRAIL R1 51 male hormones androgens 51 PI3K inhibitors 51 ovary uterus 51 medullary thyroid cancer 51 antigen PSA 51 Epratuzumab 51 papillomaviruses 51 Hsp# inhibitors 51 nodal metastasis 51 BRAF mutations 51 darapladib 51 KRAS mutations occur 51 HER2 neu 51 pre cancerous lesions 51 glioma rarer 51 cMET 51 precancers 51 premalignant 51 IGF IR 51 tyrosine kinase inhibitors 51 5 FU leucovorin 51 antiproliferative effects 51 hypereosinophilic syndrome 51 bevacizumab Avastin ® 51 premalignant lesions 51 atypical ductal hyperplasia 51 Metastatic 51 forodesine 51 novel VDA molecule 51 poly ADP ribose polymerase 51 prostate cancer mCRPC 51 Candida infections 51 invasive ductal carcinomas 51 hCG beta 51 pancreatic carcinoma 51 Endometrial cancer 51 leukemia CLL 51 metastatic kidney 51 squamous cell carcinoma SCC 51 invasive breast cancer 51 androgen receptor AR 51 sPLA2 51 Acute lymphoblastic leukemia 51 grade gliomas 51 gastric cancer 51 benign noncancerous 51 molecularly targeted 51 uterine tumors 51 malignant prostate 51 ENMD # 51 neoplasias 51 GSTP1 51 pegylated liposomal doxorubicin 51 anti EGFR antibody 51 prostate cancer CaP 51 panitumumab Vectibix 51 MYCN amplification 51 Symadex 51 esophagus colon 51 adjuvant radiotherapy 51 Velcade bortezomib 51 platinum refractory 51 prophylactic vaccines 51 HGS ETR1 mapatumumab 51 Cholangiocarcinoma 51 oral prodrug 51 adrenocortical cancer 51 gastrointestinal malignancies 51 grade serous ovarian 51 metastatic androgen independent 51 HPV 51 chronic lymphocytic leukemia CLL 51 basal cell carcinomas 51 deCODE BreastCancer TM 51 malignant pleural mesothelioma MPM 51 metastatic neuroendocrine tumors 51 cytomegalovirus infections 51 immunological diseases 51 neoadjuvant therapy 51 Taxotere docetaxel 51 sorafenib Nexavar ® 51 PARP inhibition 51 vinca alkaloids 51 axillary lymph nodes 51 KIT mutations 51 Hsp# inhibition 51 BMPR2 51 abnormal Pap smears 51 prostate tumors 51 Her2 51 commercialize deforolimus 51 prostate carcinoma 51 GnRH agonists 51 adenomatous polyp 51 Tay Sachs thalassemia 51 radiofrequency ablation RFA 51 dasatinib Sprycel 51 methylation markers 51 metastatic cancers 51 histological subtypes 51 Azedra 51 anthracycline taxane 51 NF kB pathway 51 tanespimycin 51 Epstein Barr virus EBV 51 letrozole Femara 51 metastatic melanomas 51 gastric carcinoma 51 advanced adenoma 51 BRCA1 mutation 51 MUC1 51 Seliciclib 51 malignant gliomas 51 Pap smear screening 51 vinca alkaloid 51 promoter hypermethylation 51 proliferative disorders 51 sodium thiosulfate STS 51 Glioblastoma multiforme GBM 51 relapsed leukemia 51 suppresses tumor 51 chemo resistant 51 Azixa 51 glioblastoma 51 Paraplatin ® carboplatin 51 keloid scarring 51 oncological indications 51 NSCLC tumors 51 MMP inhibitors 51 Perifosine 51 CXCR4 receptor 51 chemotherapy cisplatin 51 HBeAg negative 51 papillary 51 MLL AF9 51 EGFr 51 Targretin 51 tumor xenografts 51 INGN 51 proteasome inhibitor 51 cancerdefine 51 Sezary syndrome 51 HspE7 51 diagnostic biomarker 51 Papillary 51 paclitaxel Taxol ® 51 Exherin TM 50 vorinostat 50 colorectal adenomas 50 GBM tumors 50 oesophageal adenocarcinoma 50 JAK3 50 trastuzumab Herceptin R 50 contralateral breast 50 situ CIS 50 squamous cell lung cancer 50 anticancer therapies 50 myeloid leukemia 50 anaplastic lymphoma kinase 50 non alcoholic steatohepatitis 50 familial adenomatous polyposis 50 XmAb# 50 Merck KGaA Erbitux 50 cetuximab Erbitux ® 50 orally administered inhibitor 50 EZH2 50 Human Papillomavirus 50 hematological disorders 50 salpingo oophorectomy 50 cervical uterine 50 WT1 50 metastatic pancreatic 50 mucinous 50 adenomatous polyps 50 CDK4 50 hormonally responsive 50 induce apoptosis 50 anticancer agents 50 chemotherapeutic agents 50 MYH9 gene 50 Cell Lung Cancer 50 resistant ovarian cancer 50 liver metastasis 50 BRCA2 mutation carriers 50 lymphatic tissue 50 renal carcinoma 50 pan HDAC inhibitor 50 acute leukemias 50 mTOR inhibitors 50 advanced metastatic prostate 50 chlamydial infection 50 CD# expressing 50 grade cervical dysplasia 50 Cloretazine 50 precancerous lesions 50 oropharyngeal cancer 50 colon polyps 50 thalidomide Thalomid 50 BRCA1 BRCA2 50 breast carcinoma 50 Sudhir Agrawal D.Phil 50 CaP 50 docetaxel Taxotere R 50 epithelial ovarian 50 soft tissue sarcomas 50 carcinoid 50 squamous histology 50 KRAS mutant 50 erlotinib Tarceva 50 EGFR 50 adhesion molecule EpCAM expressing 50 alkylating agent 50 pre cancerous growths 50 HRPC 50 colorectal polyp 50 Nexavar sorafenib 50 MAGE A3 ASCI 50 VEGFR2 inhibitor 50 pulmonary metastases 50 xenograft tumors 50 dasatinib 50 Malignant Melanoma 50 PXD# 50 Irinotecan 50 chemopreventive agents 50 paclitaxel Taxol 50 Uterine fibroids 50 alkylating agents 50 PTEN mutations 50 oesophageal cancers 50 ZACTIMA 50 hepatitis C HCV 50 Prostate Lung Colorectal 50 hematopoietic malignancies 50 heavily pretreated 50 liposomal doxorubicin 50 MAGE A3 50 neuroblastomas 50 ixabepilone 50 JAK2 inhibitors 50 multi kinase inhibitor 50 BRCA gene mutation 50 differentiated thyroid 50 myeloma cells 50 Helicobacter pylori H. pylori 50 evaluating picoplatin 50 ASA# 50 CDH1 50 pancreatic endocrine 50 beta catenin protein 50 cisplatin chemotherapy 50 trans retinoic acid 50 distant metastasis 50 gynecologic cancers 50 haematopoietic 50 receptor tyrosine kinase inhibitor 50 metastatic breast 50 diseases fat malabsorption 50 VEGFR2 50 melanoma 50 familial hypercholesterolemia 50 lung tumors 50 Kaposi sarcoma 50 unresectable 50 metastatic disease 50 Cetuximab Erbitux 50 TREANDA 50 metastatic liver 50 BRAF protein 50 cell lymphomas 50 PCa 50 HER2 expression 50 metastatic HER2 negative 50 peritoneal carcinomatosis 50 GAP #B# 50 irinotecan chemotherapy 50 PARP inhibitors 50 gastrointestinal stromal tumors GIST 50 hA# 50 cytomegalovirus CMV 50 hedgehog pathway 50 APOPTONE 50 belinostat 50 HPV genotypes 50 superficial bladder cancer 50 LY# [003] 50 mutant BRAF 50 BRCA mutation carriers 50 c MYC 50 pediatric acute lymphoblastic 50 Androgen deprivation therapy 50 rNAPc2 50 colorectal polyps 50 metastatic malignant 50 serotype #A 50 ALN TTR 50 breast cancer 50 panobinostat 50 adenocarcinoma 50 afatinib 50 CCN2 50 premenopausal breast cancer 50 Fludara ® 50 oophorectomy 50 non squamous 50 curable cancers 50 hypermethylated 50 cutaneous T cell 50 acute myelogenous leukemia AML 50 peritoneal cancer 50 PCA3 scores 50 BRCA gene mutations 50 histological subtype 50 atherosclerotic lesions 50 T#I [002] 50 gastrointestinal stromal tumor GIST 50 MGd 50 PANVAC VF 50 factor receptor EGFR 50 HGPIN 50 recurrent squamous cell carcinoma 50 cirrhosis liver failure 50 Tavocept 50 sunitinib malate 50 telomerase inhibition 50 metastatic lung cancer 50 distal colon cancer 50 Virulizin ® 50 solar keratosis 50 CD# monoclonal antibody 50 astrocytomas 50 metastatic bladder 50 lintuzumab 50 hereditary predisposition 50 DAVANAT 50 LHRH analogues 50 malignant neoplasm 50 thyroid carcinomas 50 refractory chronic myeloid 50 colon cancer 50 lymphoid malignancies 50 chemotherapeutics 49 docetaxel Taxotere ® 49 colorectal tumor 49 estrogen receptor ER 49 AVASTIN 49 Cloretazine R 49 HER3 49 breast cancer susceptibility genes 49 angiogenesis inhibitor 49 HPV types 49 ganetespib 49 hematopoietic cell 49 malignant growths 49 hepatoma 49 inhibit tumor 49 node metastases 49 CR# vcMMAE 49 refractory metastatic 49 Her-2/neu 49 pancreatic islet 49 unresectable stage 49 BRAF inhibitor 49 metastatic tumors 49 immunotherapies 49 investigational compounds 49 essential thrombocythemia ET 49 BRCA1 gene 49 pheochromocytoma 49 GRN#L 49 Human Papilloma Virus 49 recurrent glioblastoma multiforme 49 nucleoside analogues 49 LBH# 49 Squamous cell carcinomas 49 prostate tumor 49 cell lymphoma CTCL 49 apigenin 49 gastroesophageal junction 49 metastatic hormone refractory 49 thymalfasin 49 antisense inhibition 49 metastases 49 AAT deficiency 49 mutated K ras 49 diffuse gastric 49 APOL1 49 neck squamous cell 49 prostate abnormalities 49 malignant polyps 49 inhibited tumor 49 ansamycin 49 xenograft tumor models 49 HCV infections 49 non squamous NSCLC 49 oncogenic transformation 49 colon pancreatic 49 imetelstat 49 Omacetaxine 49 leukemia ALL 49 HRPC ovarian cancer 49 narcolepsy cataplexy 49 BCG refractory 49 breast cancer gene mutation 49 Myelodysplastic syndromes MDS 49 oncoproteins 49 untreated metastatic melanoma 49 targeting CD# 49 ALK mutations 49 iniparib 49 HPV subtypes 49 tubulin inhibitor 49 metastatic 49 Glioblastomas 49 anti angiogenic therapy 49 essential thrombocythemia 49 pre cancerous 49 Chronic Lymphocytic Leukemia CLL 49 pancreatic islet cell 49 cutaneous melanoma 49 gastric adenocarcinoma 49 FOLOTYN ® 49 nanomolar 49 cytotoxic 49 noncancerous tumors 49 lobular 49 relapsed MM 49 Metastases 49 glioblastoma tumors 49 AQ4N 49 PLX# 49 microvascular disease 49 chemotherapeutic drugs 49 cediranib 49 metastatic carcinoid 49 antiangiogenesis therapies 49 Renal Cell Carcinoma RCC 49 AEGR 49 NNRTI resistance 49 Amrubicin 49 transgenic rats 49 cervix uteri 49 cervical neoplasia 49 Neulasta ® 49 metastatic renal 49 MDV# 49 Erbitux cetuximab 49 EOquin 49 prostate cancer 49 FGFR2 gene 49 pneumococcal serotypes 49 mutant p# 49 BRCA1 49 dasatinib Sprycel ® 49 CTAP# Capsules 49 Invasive Breast Cancer 49 nonvaccine 49 Aplidin 49 Raf MEK ERK 49 herpes zoster shingles 49 cervical vulvar 49 HER2/neu 49 dutasteride 49 exemestane Aromasin 49 DHFR 49 FOLFOX chemotherapy 49 gynecologic cancer 49 HDAC inhibitor 49 commonest cancers 49 preclinically 49 survivin 49 R sorafenib tablets 49 decitabine 49 C. trachomatis 49 rectal cancer 49 HCV infection 49 OGG1 49 EGFRvIII 49 radiation sensitizer 49 lymphoproliferative disorders 49 nilotinib Tasigna ® 49 Breast Cancers 49 YONDELIS 49 untreated celiac disease 49 deforolimus 49 hormone refractory prostate cancer 49 OPAXIO 49 HNPCC 49 lymph node metastases 49 leiomyomas 49 metastatic renal cell 49 nonproliferative 49 ALCL 49 relapsed acute lymphoblastic 49 secretory diarrhea 49 bacterial vaginosis BV 49 systemic lupus erythematosus SLE 49 PIK3CA 49 carboplatin paclitaxel 49 KRAS mutation 49 bafetinib 49 BRCA1 gene mutation 49 syngeneic 49 MetAP2 49 cervical cancers 49 pre malignant lesions 49 ZADAXIN ® 49 T DM1 49 xenografts 49 chromosomal rearrangement 49 interleukin IL -# 49 Human papilloma virus 49 radiosensitive 49 chemopreventive 49 XL# inhibits 49 premalignant lesion 49 chemoattractant receptors 49 carcinoma 49 Rituxan rituximab 49 Gliomas 49 relapsed acute myelogenous 49 autoantibody positive 49 melanoma tumors 49 malignant ovarian 49 follicular lymphoma FL 49 breast cancer genes BRCA1 49 antiestrogen 49 Squamous cell cancer 49 prostate adenocarcinoma 49 induces apoptosis 49 talabostat 49 causes genital warts 49 CA4P 49 targeted kinase inhibitor 49 Exelixis compounds 49 Xanafide 49 Hycamtin 49 Sym# 49 myelodysplastic syndrome MDS 49 benign moles 49 Annamycin 49 urothelial carcinoma 49 ABCB1 49 histone deacetylase inhibitor 49 hematological diseases 49 Crizotinib 49 sarcomas 49 bevacizumab Avastin